Trial Profile
A study evaluating Resting Energy Expenditure as a prdictor of response to Nivolumab in patients with metastatic non small cell lung cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 20 Apr 2018 New trial record
- 18 Apr 2018 Results presented at the 109th Annual Meeting of the American Association for Cancer Research